111 related articles for article (PubMed ID: 19433978)
21. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
22. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
27. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
28. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins M; Schutte M; Lu J; Moskaluk CA; Weinstein CL; Petersen GM; Yeo CJ; Jackson CE; Lynch HT; Hruban RH; Kern SE
Cancer Res; 1996 Dec; 56(23):5360-4. PubMed ID: 8968085
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Zhou JF; Bai CM; Cheng YJ; Jia N; Shao YJ; Chen SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):358-61. PubMed ID: 19621525
[TBL] [Abstract][Full Text] [Related]
30. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
[TBL] [Abstract][Full Text] [Related]
32. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells.
Abbott DW; Freeman ML; Holt JT
J Natl Cancer Inst; 1998 Jul; 90(13):978-85. PubMed ID: 9665145
[TBL] [Abstract][Full Text] [Related]
33. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract][Full Text] [Related]
34. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Petitprez A; Poindessous V; Ouaret D; Regairaz M; Bastian G; Guérin E; Escargueil AE; Larsen AK
Int J Oncol; 2013 May; 42(5):1644-53. PubMed ID: 23546019
[TBL] [Abstract][Full Text] [Related]
35. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer.
Yildirim HC; Ismayilov R; Akyildiz A; Guven DC; Abdurrahimli N; Dizdar O; Yalcin S
Anticancer Drugs; 2023 Nov; 34(10):1190-1192. PubMed ID: 36729128
[TBL] [Abstract][Full Text] [Related]
36. Acquired multiple secondary
Tao H; Liu S; Huang D; Han X; Wu X; Shao YW; Hu Y
Am J Transl Res; 2020; 12(2):612-617. PubMed ID: 32194909
[TBL] [Abstract][Full Text] [Related]
37. Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.
Thomas AM; Hui C; South A; McVey M
G3 (Bethesda); 2013 Jan; 3(1):91-9. PubMed ID: 23316441
[TBL] [Abstract][Full Text] [Related]
38. Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Amzerin M; Mokrim M; Errihani H; Piccart MJ
J Med Case Rep; 2015 Feb; 9():5. PubMed ID: 25971303
[TBL] [Abstract][Full Text] [Related]
39. Familial pancreatic cancer.
Petersen GM
Semin Oncol; 2016 Oct; 43(5):548-553. PubMed ID: 27899186
[TBL] [Abstract][Full Text] [Related]
40. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
